STOCK TITAN

Novan to Report First Quarter 2023 Financial Results on May 15, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Novan, Inc. will report its Q1 2023 financial results on May 15th and host a conference call to discuss the results. The call will be led by President and CEO Paula Brown Stafford.
Positive
  • Novan, Inc. will report its Q1 2023 financial results on May 15th.
Negative
  • None.

DURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2023 financial results on Monday, May 15th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.

The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the Novan management team. Interested participants and investors may access the conference call by dialing (833) 630-1956 (domestic) or (412) 317-1837 (international) and referencing the Novan, Inc. Conference Call. The live webcast will be accessible on the Events page of the Investors section of the Novan website, novan.com, and will be archived for 90 days.

About Novan

Novan, Inc. is a medical dermatology company focused on developing and commercializing innovative therapeutic products for skin diseases. Our goal is to deliver safe and efficacious therapies to patients, including developing product candidates where there are unmet medical needs. Novan has a robust commercial infrastructure across sales, marketing, and communications, as well as fully dedicated market access and pharmacy relation teams, promoting products for plaque psoriasis, rosacea and acne. The U.S. Food and Drug Administration (“FDA”) accepted for filing Novan’s New Drug Application (“NDA”) seeking approval for berdazimer gel, 10.3% (SB206) for the treatment of molluscum contagiosum. The Company also has a pipeline of potential product candidates using its proprietary nitric oxide-based technology platform, NITRICIL™, to generate new treatments for multiple indications.

INVESTOR AND MEDIA CONTACT:

Jenene Thomas
JTC Team, LLC
833-475-8247
NOVN@jtcir.com


FAQ

When will Novan, Inc. report its Q1 2023 financial results?

Novan, Inc. will report its Q1 2023 financial results on Monday, May 15th.

Who will lead the conference call to discuss the results?

The conference call to discuss the results will be led by Paula Brown Stafford, President and CEO of Novan, Inc.

How can participants access the conference call?

Interested participants and investors may access the conference call by dialing (833) 630-1956 (domestic) or (412) 317-1837 (international) and referencing the Novan, Inc. Conference Call.

Where can the live webcast be accessed?

The live webcast will be accessible on the Events page of the Investors section of the Novan website, novan.com.

How long will the webcast be archived?

The webcast will be archived for 90 days.

NOVN

NASDAQ:NOVN

NOVN Rankings

NOVN Latest News

NOVN Stock Data

2.64M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Morrisville

About NOVN

novan, inc. is a clinical-stage biotechnology company focused on leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. we believe that our ability to conveniently deploy nitric oxide in a solid form, on demand and in localized formulations allows us the potential to significantly improve patient outcomes in a variety of diseases.